TY  - JOUR
AU  - Kratochwil, C.
AU  - Stefanova, M.
AU  - Mavriopoulou, E.
AU  - Holland-Letz, T.
AU  - Dimitrakopoulou-Strauss, A.
AU  - Afshar-Oromieh, A.
AU  - Mier, W.
AU  - Haberkorn, U.
AU  - Giesel, Frederik
TI  - SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors.
JO  - Molecular imaging & biology
VL  - 17
IS  - 3
SN  - 1860-2002
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2017-02948
SP  - 313 - 318
PY  - 2015
AB  - The goal of our study was to quantify the expression of the somatostatin receptors (SSTR2) using the maximum standardized uptake value (SUVmax) of [(68)Ga]DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron emission tomography (PET)-computed tomography (CT) in liver metastases of patients with neuroendocrine tumors (NETs) prior to peptide receptor radiation therapy (PRRT) and compare the initial tumor uptake with the final treatment outcome.SSTR2 expression of the 60 liver metastases in 30 NET patients was assessed at baseline and after PRRT by measuring SUVmax, tumor to spleen ratio (T/S ratio), and tumor to liver ratio (T/L ratio). Based on morphological changes and tumor size measured at baseline and follow-up contrast-enhanced CT (after three cycles of PRRT), lesions were divided into two groups by the following: (i) responding (n = 40) and (ii) non-responding (n = 20).Statistically significant differences were observed in the mean SUVmax for non-responding vs. responding lesions at baseline (18.00 ± 3.59 vs. 33.55 ± 4.62, p < 0.05) and for the mean T/S ratio (1.20 ± 0.37 vs. 1.90 ± 0.45, p < 0.05) and the mean T/L ratio (3.15 ± 0.53 vs. 4.97 ± 0.62, p < 0.05). Using the receiver operating characteristic curves, SUVmax was found a better metric than both T/L ratio and T/S ratio (area under the curve (AUC) of SUVmax 0.87; T/L ratio 0.78; T/S ratio 0.73) as a stratification criterion. Using a threshold value of >16.4 for SUVmax, the sensitivity and specificity in predicting responding lesions were 95 and 60 
KW  - Contrast Media (NLM Chemicals)
KW  - Ga(III)-DOTATOC (NLM Chemicals)
KW  - Organometallic Compounds (NLM Chemicals)
KW  - Peptides (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
KW  - Receptors, Somatostatin (NLM Chemicals)
KW  - somatostatin receptor subtype 2, human (NLM Chemicals)
KW  - Octreotide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25319765
DO  - DOI:10.1007/s11307-014-0795-3
UR  - https://inrepo02.dkfz.de/record/126920
ER  -